Korea Warns of Rare Vision-Loss Risk Linked to GLP-1 Drugs
4 Articles
4 Articles
The Ministry of Food and Drug Safety announced that users of obesity and diabetes medications, such as Wigobi and Maunzaro, must immediately notify medical staff if sudden vision loss occurs. On the 11th, the Ministry [stated] regarding ‘non-arteritic anterior ischemic optic neuropathy’ (NAION) while using glucagon-like peptide-1 (GLP-1) class drugs
(Seoul = Yonhap News) Reporter Shin Seon-mi = The Ministry of Food and Drug Safety [announced] that non-arteritic anterior ischemic optic neuropathy (N...) when using glucagon-like peptide-1 (GLP-1) class drugs
EOF President Spyros Sapounas explains what is true about the association of GLP-1 drugs, such as Ozempic and semaglutide, with the rare eye condition NAION. What the EMA says, what the risks are and why patients should not arbitrarily discontinue their treatment.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
